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ssessing Niacin as
n Atherosclerosis
herapeutic Agent
aluable Insights Provided
y High-Resolution Vascular
agnetic Resonance Imaging*
arouc A. Jaffer, MD, PHD
oston, Massachusetts
espite the substantial clinical benefit offered by potent
ow-density lipoprotein (LDL)-reducing therapeutics such
s statins, a majority of patients will still experience major
ardiovascular events (1). Accordingly, there exists a large,
nmet need for new atherosclerosis therapeutic strategies
hat will further reduce cardiovascular disease (CVD)
vents.
Nicotinic acid (NA), or niacin, is an intriguing candidate
herapy for CVD, and in fact has been investigated as an
therosclerosis therapy for over 40 years. A number of
linical outcome studies and, notably, imaging studies have
emonstrated consistent benefits of niacin (2). Yet, remark-
bly only a few trials have studied niacin in combination
ith statin therapy, with limitations of the lack of a statin
onotherapy arm (3) or the use of modest dosages of niacin
4,5). So, does high-dose niacin (2 g/day) provide antiath-
rosclerotic benefits when administered to statin-treated
atients with vascular disease?
See page 1787
In this issue of the Journal, Lee et al. (6) utilize high-
esolution vascular magnetic resonance imaging (MRI) to
rovide valuable insights into the effects of niacin on carotid
therosclerosis. The authors performed a placebo-controlled,
ouble-blind, single-center, randomized study of high-dose
iacin (2 g/day) in 71 patients with established atherosclerotic
ascular disease and a low high-density lipoprotein cholesterol
HDL-C) level (40 mg/dl). All patients received effective
tatin therapy on entry, with a baseline low-density lipoprotein
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.r
From the Cardiovascular Research Center and Cardiology Division, Massachusetts
eneral Hospital, Boston, Massachusetts.holesterol (LDL-C) level of 85 mg/dl, at target for high-risk
atients (7). Patients were randomized to receive modified
elease NA or placebo for 1 year. NA was initiated at 375 mg
aily and titrated up to 2,000 mg daily over approximately
months.
The primary end point of the study was the absolute
hange in carotid artery wall area as determined by MRI.
atients underwent electrocardiogram-gated 1.5-T vascular
RI at baseline, 6 months, and 12 months. A multiterri-
ory, multifunctional MRI study was performed to assess
arotid wall area, aortic wall area, aortic distensibility, and
rachial artery vascular response to flow-mediated dilation
r glyceryl trinitrate, based on protocols developed in the
nvestigators’ and others’ laboratories (8–10).
A total of 59 of 71 patients completed the study, with
reater dropout in the NA arm (63% study completion)
ompared with the placebo group (81% study completion).
ifferences in the dropout rates reflected the known side-
ffect profile of niacin such as flushing, itching, and gastro-
ntestinal symptoms. Encouragingly, the authors did not
eport NA withdrawal for more serious side-effects such as
levated liver function tests or elevated creatine kinase levels.
ithdrawal due to claustrophobia during MRI was a minor
omponent (10% in both arms).
After 12 months, the primary end point was met, with
vidence of carotid wall area regression in the NA group
1.1  2.6 mm2) compared with progression in the
lacebo group (1.2  3.0 mm2, p  0.03). In the aorta,
here was a significant reduction in vessel wall area at 6
onths of NA therapy, but this result was not significant at
2 months, possibly due to an insufficient sample size.
low-mediated dilation of the brachial artery showed a
avorable trend with NA therapy. Aortic distensibility and
lyceryl-trinitrate–mediated brachial reactivity did not
hange significantly with NA therapy.
ipid Effects
he effects of niacin on the lipid parameters were as
xpected with high-dose niacin—a 23% increase in HDL-C
evels and 19% reduction in LDL-C levels. Study limita-
ions included the lack of information on diet and exercise,
actors that affect lipid levels. Given the multiple lipid effects
f niacin, what mechanisms might explain the observed
enefit of NA on carotid plaque area? To address this
uestion, the authors analyzed scatterplots of the change in
arotid wall area versus the change in the HDL-C and
DL-C levels. Analyses revealed an inverse relationship
etween the HDL-C level and wall area, and no evident
elationship between the LDL-C level and wall area. These
esults further strengthen the concept that niacin-based
ncreases in HDL-C may be beneficial, despite recent
xperiences with other HDL-C–augmenting agents (2).
owever, it is important to recognize that niacin alsoeduces triglyceride, lipoprotein (a), and apolipoprotein B
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Niacin and Carotid MRI November 3, 2009:1795–6evels, as observed here and in other studies. Potential
enefits of niacin may therefore be due to multiple factors.
omparison With Other Imaging Studies
wo prior randomized NA trials incorporated a mono-
herapy statin control arm and investigated moderate dose
A therapy (1 g/day) or placebo for 12 months in 167
atients (4,5). These studies also employed imaging to
rovide a surrogate end point, namely B-mode ultrasound
arotid intima-media thickness (IMT). In the ARBITER-2
Arterial Biology for the Investigation of the Treatment
ffects of Reducing Cholesterol 2) study, the primary end
oint of reduced change in the common carotid IMT did
ot reach statistical significance (p  0.08), although
ignificance was reached at 24 months in the cross-over,
pen-label extension study (5). As carotid MRI may offer
mproved sensitivity compared with carotid IMT (11),
uture atherosclerosis imaging trials may benefit from em-
loying both modalities.
lternative Imaging End Points
RI offers the added ability to evaluate plaque composi-
ion. While not investigated in the current study due to
tated low prevalence, it may be important to ascertain
hether NA therapy reduces carotid plaque lipid-rich/
ecrotic cores, a risk factor for cerebrovascular ischemic
vents (12). In addition, inflammation, a major driving force
f plaque complications, is an important molecular imaging
arget for many atherosclerosis therapeutic agents (13).
ndeed, clinical molecular MRI and positron emission
omography imaging studies show that statins significantly
educe plaque inflammation. Will niacin further reduce
laque inflammation in statin-treated patients?
maging as a Surrogate End Point
or Atherosclerosis Therapeutics
therosclerosis imaging can provide surrogate end points
or therapeutic efficacy, namely plaque regression. While
maging end points are unlikely to result in a candidate drug
pproval by the Food and Drug Administration, atheroma
maging studies can provide direct evidence of atheroma
herapies on the vessel wall, and therefore rationally moti-
ate larger outcome trials. In the case of niacin, such studies
re well underway (14,15).
onclusions
his important study by Lee et al. (6) provides direct MRI
vidence that niacin reduces carotid atherosclerosis in
tatin-treated patients with low HDL-C levels. These hesults strengthen the hypothesis that combination niacin
tatin therapy will reduce CVD events compared with statin
onotherapy. We eagerly await the results of these ongoing
ivotal trials (14,15).
eprint requests and correspondence: Dr. Farouc A. Jaffer,
GH CVRC, Simches Research Building, Room 3206, 185
ambridge Street, Boston, Massachusetts 02114. E-mail:
jaffer@mgh.harvard.edu.
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